Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 21 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-205.92 Insider Own0.53% Shs Outstand6.57M Perf Week71.21%
Market Cap8.21M Forward P/E- EPS next Y-0.67 Insider Trans0.00% Shs Float6.54M Perf Month172.33%
Income-17.06M PEG- EPS next Q-0.65 Inst Own6.35% Short Float2.29% Perf Quarter86.57%
Sales0.00M P/S- EPS this Y98.09% Inst Trans-1.96% Short Ratio0.13 Perf Half Y-88.07%
Book/sh0.79 P/B1.58 EPS next Y66.16% ROA-264.82% Short Interest0.15M Perf Year-99.45%
Cash/sh0.75 P/C1.67 EPS next 5Y- ROE-784.63% 52W Range0.42 - 309.60 Perf YTD-81.04%
Dividend Est.- P/FCF- EPS past 5Y-28.81% ROI-372.05% 52W High-99.60% Beta0.31
Dividend TTM- Quick Ratio2.48 Sales past 5Y0.00% Gross Margin- 52W Low197.62% ATR (14)0.24
Dividend Ex-Date- Current Ratio2.48 EPS Y/Y TTM81.88% Oper. Margin0.00% RSI (14)62.00 Volatility25.45% 32.05%
Employees10 Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price3.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q99.76% Payout- Rel Volume0.74 Prev Close1.19
Sales Surprise- EPS Surprise-125.93% Sales Q/Q- EarningsApr 01 BMO Avg Volume1.14M Price1.25
SMA2052.09% SMA5076.80% SMA200-91.60% Trades Volume839,121 Change5.04%
May-13-24 10:20AM
Apr-15-24 09:00AM
09:10AM Loading…
Apr-03-24 09:10AM
Mar-28-24 08:30AM
Mar-11-24 09:00AM
Mar-06-24 04:15PM
Feb-20-24 08:00AM
Jan-31-24 04:05PM
Jan-29-24 08:30AM
Jan-22-24 04:45PM
Jan-19-24 01:09PM
Jan-18-24 01:27PM
04:05PM Loading…
Jan-12-24 04:05PM
Jan-11-24 08:00AM
Jan-04-24 08:05AM
Dec-12-23 08:30AM
Dec-05-23 09:00AM
Dec-04-23 04:10PM
Nov-30-23 02:53PM
Nov-14-23 04:30PM
Oct-30-23 04:33PM
Oct-27-23 08:16AM
Oct-26-23 04:19PM
Oct-24-23 08:00AM
Oct-16-23 08:00AM
04:02PM Loading…
Sep-28-23 04:02PM
Sep-25-23 08:01PM
Aug-23-23 08:00AM
Aug-14-23 04:45PM
Jul-31-23 07:00AM
Jul-13-23 12:43PM
Jul-10-23 09:55AM
Jul-05-23 07:00AM
Jun-28-23 03:49PM
Jun-23-23 09:24AM
Jun-22-23 07:00AM
Jun-09-23 04:05PM
Jun-07-23 11:00AM
Jun-06-23 05:29PM
May-22-23 07:00AM
Apr-27-23 07:00AM
Apr-26-23 08:00AM
Apr-14-23 07:00AM
Apr-06-23 07:00AM
Apr-05-23 07:00AM
Apr-04-23 09:00PM
Apr-03-23 08:00AM
Mar-31-23 04:01PM
Feb-28-23 07:00AM
Feb-22-23 08:00AM
Feb-18-23 08:42AM
Feb-17-23 04:10PM
Feb-16-23 08:00AM
Feb-01-23 07:49AM
Jan-31-23 04:05PM
Dec-29-22 09:34AM
Dec-07-22 02:37PM
Dec-06-22 04:20PM
Nov-30-22 07:00AM
Nov-14-22 04:15PM
Nov-09-22 07:00AM
Nov-08-22 03:40PM
Nov-07-22 08:00AM
Oct-26-22 10:51AM
Oct-19-22 08:00AM
Oct-13-22 07:00AM
Sep-27-22 08:00AM
Sep-08-22 08:00AM
Aug-15-22 04:15PM
Aug-02-22 07:00AM
Jul-11-22 04:05PM
Jul-04-22 03:13PM
Jun-09-22 09:00AM
Jun-01-22 09:00AM
May-20-22 09:00AM
May-19-22 09:00AM
May-16-22 08:30AM
Apr-13-22 09:00AM
Apr-05-22 07:17AM
Mar-31-22 04:30PM
Mar-25-22 12:00PM
Mar-23-22 09:00AM
Feb-14-22 09:00AM
Feb-10-22 09:46AM
Jan-06-22 03:17PM
Dec-06-21 07:10PM
Nov-18-21 10:57AM
Nov-15-21 04:01PM
Nov-09-21 07:30AM
Sep-30-21 04:01PM
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dudley Robert MichaelChief Executive OfficerSep 28 '23Buy0.5198,00049,980180,262Oct 02 04:37 PM
Fitzgerald Thomas AChief Financial OfficerSep 28 '23Buy0.5149,35025,16856,318Oct 02 04:39 PM
Dudley Robert MichaelChief Executive OfficerJun 21 '23Buy2.6512,00031,81882,262Jun 22 06:23 PM
Dudley Robert MichaelChief Executive OfficerJun 20 '23Buy2.556,60716,84770,262Jun 22 06:23 PM
Dudley Robert MichaelChief Executive OfficerJun 09 '23Buy2.7619,00052,440912,114Jun 13 04:16 PM